NOW AVAILABLE: ADA 2013 Conference Coverage

Experts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.

Experts say COPD care should aim for disease stability, with advanced therapy a routine next step, not a last resort, for patients who fall short.

Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.

Gerald Criner, MD, outlines which patients with advanced COPD may need oxygen, home NIV, or high-flow therapy and when to discuss goals of care.

The 2026 meeting in Denver features more than 265 hours of programming, real-world MASH treatment data, and late-breaking results in rare liver diseases.

The GOLD International COPD Conference will cover underdiagnosis, exacerbations, mucus, biologics, and a preview of the 2027 GOLD Report.

Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

Leaders from Boehringer Ingelheim, Incyte, Pfizer, and Takeda told the audience at Patient-Centered Oncology Care® that artificial intelligence (AI) is compressing discovery timelines, but that gaps in testing, data, and community access still decide which patients benefit.